Stock Analysis

Discovering MEISEI INDUSTRIALLtd And 2 Other Hidden Japanese Small Caps With Strong Potential

TSE:4569
Source: Shutterstock

As Japan’s stock markets experience a downturn, with the Nikkei 225 Index down 5.8% and the broader TOPIX Index registering a 4.2% loss, investors are increasingly looking for opportunities in small-cap stocks that may offer resilience and growth potential amid broader market volatility. In this environment, identifying companies with strong fundamentals and unique market positions can be crucial for uncovering hidden gems.

Top 10 Undiscovered Gems With Strong Fundamentals In Japan

NameDebt To EquityRevenue GrowthEarnings GrowthHealth Rating
Ryoyu SystemsNA1.08%8.08%★★★★★★
NJSNA4.97%5.30%★★★★★★
Kanda HoldingsLtd30.47%4.35%18.02%★★★★★★
Poppins39.80%8.36%-7.40%★★★★★★
Ad-Sol NissinNA4.02%7.90%★★★★★★
Otec9.81%2.32%-1.39%★★★★★★
NPR-Riken15.31%10.00%44.55%★★★★★☆
Toho82.16%1.83%47.38%★★★★★☆
AJIS0.69%0.07%-12.44%★★★★★☆
Pharma Foods International191.14%33.83%23.46%★★★★★☆

Click here to see the full list of 749 stocks from our Japanese Undiscovered Gems With Strong Fundamentals screener.

Below we spotlight a couple of our favorites from our exclusive screener.

MEISEI INDUSTRIALLtd (TSE:1976)

Simply Wall St Value Rating: ★★★★★★

Overview: MEISEI INDUSTRIAL Co., Ltd. operates as a construction works company in Japan and internationally with a market cap of ¥57.43 billion.

Operations: MEISEI INDUSTRIAL Co., Ltd. generates revenue primarily from its Construction Work segment (¥55.55 billion) and Boiler Business (¥7.45 billion).

MEISEI INDUSTRIAL Ltd., a small cap, has shown impressive growth with earnings increasing by 44.4% over the past year, outpacing the Construction industry’s 25.5%. The company's debt to equity ratio improved from 2.1% to 1.2% in five years, reflecting prudent financial management. Trading at 54.4% below estimated fair value suggests potential for significant upside. With high-quality earnings and more cash than total debt, MEISEI seems well-positioned for continued stability and growth in its sector.

TSE:1976 Debt to Equity as at Sep 2024
TSE:1976 Debt to Equity as at Sep 2024

KYORIN Pharmaceutical (TSE:4569)

Simply Wall St Value Rating: ★★★★★☆

Overview: KYORIN Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells ethical and generic drugs in Japan and internationally with a market cap of ¥88.13 billion.

Operations: KYORIN Pharmaceutical generates revenue primarily from its pharmaceutical business, which reported ¥120.10 billion in revenue. The company's net profit margin stands at 5.23%.

Kyorin Pharmaceutical, a small-cap player in the Japanese market, has shown robust earnings growth of 31.2% over the past year, outpacing the industry average of 8.6%. The company's debt to equity ratio improved from 19.4% to 15.9% over five years, indicating prudent financial management. Trading at a price-to-earnings ratio of 15.9x compared to the industry average of 17.6x suggests it offers good value for investors looking at pharmaceuticals in Japan.

TSE:4569 Earnings and Revenue Growth as at Sep 2024
TSE:4569 Earnings and Revenue Growth as at Sep 2024

Mitsuboshi Belting (TSE:5192)

Simply Wall St Value Rating: ★★★★★★

Overview: Mitsuboshi Belting Ltd. manufactures and sells power transmission belts, waterproofing and water shielding sheets, and engineering plastics and structural foams in Japan and internationally, with a market cap of ¥112.91 billion.

Operations: The company generates revenue primarily from the sale of power transmission belts, waterproofing and water shielding sheets, and engineering plastics and structural foams. The cost structure includes manufacturing expenses related to these products. Net profit margin trends are notable for their variability over recent periods.

Mitsuboshi Belting, a smaller player in the machinery sector, has shown impressive earnings growth of 29.5% over the past year, outpacing the industry's 12.9%. With a debt-to-equity ratio reduced from 11.7% to 6.1% over five years and more cash than total debt, financial stability is evident. The company also enjoys a favorable price-to-earnings ratio of 12.1x compared to the JP market's 13.2x, indicating potential value for investors.

TSE:5192 Earnings and Revenue Growth as at Sep 2024
TSE:5192 Earnings and Revenue Growth as at Sep 2024

Taking Advantage

Searching for a Fresh Perspective?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if KYORIN Pharmaceutical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com